Understanding the FDA’s Stricter EMC Requirements for Common Electromagnetic Emitters

Recently, many companies undergoing FDA 510(k) EMC review have received similar requests for additional information:

• Please provide immunity data related to 5G

• Please explain how the device performs in RFID environments

• Please provide a risk analysis for common EM emitters

Many engineers are baffled: “We have already completed all EMC tests according to IEC 60601-1-2 – why do we need extra tests for 5G and RFID?”

The reason is actually very simple: the coverage of international standards cannot keep up with changes in the real-world electromagnetic environment, and the FDA requires companies to take responsibility for real-world conditions.

The source of these requests is Section J: Common Electromagnetic Emitters in the FDA’s latest EMC guidance.

IEC 60601-1-2 does not cover all real-world interference

Most companies believe that completing EMC testing to IEC 60601-1-2 means everything is fine.

But in reality:

• There are many RFID frequency bands (some not included in 60601-1-2)

• 5G bands are expanding rapidly (especially Sub-6 GHz and millimetre wave)

• Wireless power transfer (WPT / Qi) interference characteristics are complex and constantly evolving

• Metal detector gates and EAS security gates generate strong low-frequency magnetic fields not covered by the standard

• Interference from high-power equipment such as electrosurgical units in hospitals differs from standard test conditions

In other words:

Testing to the standard ≠ covering all real interference sources

“Sufficient” per the standard does not mean the device can be used safely

That is why the FDA created a separate Section J in the new guidance.

Why is the FDA paying more attention to 5G / RFID?

The FDA states clearly in the guidance: “Many common electromagnetic emitters are not fully covered by FDA-recognised EMC standards and must therefore be assessed additionally.”

These emitters include:

• RFID systems (hospital asset management, pharmacies, access control)

• EAS anti-theft gates in shops

• NFC payment and phone tap features

• Wireless power transfer (Qi wireless charging)

• 5G (especially the new FR1/FR2 bands)

• Special medical emitters (electrosurgical units, defibrillators, diathermy equipment)

• Metal detector gates and industrial equipment

The FDA’s reasoning is clear: the clinical environment is far more complex than the laboratory, and medical devices must work reliably in the real environment.

In particular, several real adverse events have shown that:

• RFID tag antennas near medical devices caused jumps in monitored ECG signals

• 5G base stations interfered with certain portable devices with low immunity

• EAS gates in supermarkets/pharmacies caused distorted alarms in implanted devices

These real cases are an important reason why the FDA updated its guidance.

Typical reasons why the FDA issues requests for additional information

The following are common patterns in FDA EMC requests:

① The company only tested to 60601-1-2 and did not assess additional bands

For example:

• 60601 testing covered 80 MHz – 2.7 GHz

• But 5G NR (Sub-6 GHz, 3.3–4.2 GHz) was not tested

• Nor was low-frequency RFID (125 kHz, 13.56 MHz)

• Nor was UHF RFID (860–960 MHz)

The FDA will then ask: “Please explain why these bands do not apply to your device.”

Many companies cannot answer – because they really did not assess them.

② The risk management file (ISO 14971) did not consider these interference sources

What the FDA values most is not the testing but the logic: “Are you aware that these emitters exist in the real environment?”

If risk management does not mention RFID / 5G / WPT, the FDA considers that:

• The risk assessment is insufficient

• The EMC declaration is incomplete

• Test coverage is inadequate

③ The instructions for use (IFU) lack EMC warnings and separation distances

Section K of the FDA guidance requires:

• EMC degraded performance

• Separation distances

• Use scenarios to avoid

• Compatible accessories

Missing these → request for additional information

④ The company claims “not affected by 5G interference” without test evidence

The FDA’s policy is:

Whenever you make a performance claim, you must provide scientific data to support it.

Many companies write in their instructions for use:

• “This device is not affected by Wi-Fi, 5G or RFID interference”

But without data → a request is certain.

Where do the FDA’s requirements for additional testing come from?

The answer comes from the official FDA guidance “Electromagnetic Compatibility (EMC) of Medical Devices” (Section J: Common Electromagnetic Emitters)

That section clearly states:

Bands not covered by the standards must be assessed by the company through

• Additional testing

• Engineering analysis

• Risk management

• Labelling warnings

to assess them.

For high-risk devices, the FDA may require dedicated testing

For example:

• Ventilators

• Infusion pumps

• Cardiac support devices

• External accessories of implanted devices

The FDA’s original wording: “Certain common EM emitters may not be adequately covered by current consensus standards. Sponsors should assess these emitters based on the use environment and risk.” In other words, additional testing is not an ad hoc idea of the FDA but a regulatory requirement.

How can companies avoid EMC requests for additional information? The following combines the FDA guidance’s explicit recommendations with practical experience:

1. Include all common emitters in risk management (especially 5G / RFID)

For healthcare environments, include:

• RFID access control / pharmacy systems

• EAS anti-theft gates

• Electrosurgical units, defibrillators

• On-site base stations in hospitals (5G, Wi-Fi, WPT)

For home environments, include:

• Routers

• Microwave ovens

• 5G / 4G mobile phones

• Wireless charging pads

2. If you do not perform these tests, you must explain why

For example:

• No RF-sensitive chips → engineering analysis is sufficient

• Device has a well-shielded metal enclosure → provide structural evidence

• Used only in professional healthcare environments → justify based on environmental analysis

But you must always “explain” – you cannot stay silent.

3. For high-risk devices, additional RFID / 5G testing is recommended

Especially for:

• Ventilators

• Infusion pumps

• Patient monitors

• Devices with wireless functions

4. Add EMC information and distance warnings to the IFU

For example:

“Avoid using this device within 1 metre of RFID access control systems.”

5. Build an “EMC environment coverage matrix”

Presenting:

• Bands covered by 60601-1-2

• Interference bands in the real environment

• Bands to which the device is sensitive

In a table → the FDA will love it.

Comparison table: IEC 60601-1-2 coverage vs real-world emitters

Conclusion: don’t treat EMC testing as a box-ticking exercise. The FDA cares about the real world, and the real-world electromagnetic environment changes far faster than standards are updated.

The FDA EMC guidance makes it clear that:

• Companies must take responsibility for real emitters

• Devices must operate safely in the intended environment

• You cannot simply test only as far as the standard goes

Without advance preparation, a request for additional information is inevitable.

So, to reduce FDA EMC requests, you must put “Section J” at the heart of your EMC strategy.

More articles:

Why Is Amazon Full of “Home Nebulizers”? The Truth Hidden Between FDA Regulations and Amazon Policy

The CE-MID Directive Explained: Don’t Mistake Laboratory Instruments for Legal Metrology Equipment

[EVERBIZ EU Regulations Column] Which Products Fall Under the EU GPSD? Why Do Some Consumer Products Need CE Marking and Others Don’t?

Key Changes in China’s New Medical Device GMP: Effective 2026 – A Must-See Comparison Table

Japan PSE Certification Explained | Application Steps, Testing Requirements and Labelling Rules